Matches in Wikidata for { <http://www.wikidata.org/entity/Q66396125> ?p ?o ?g. }
Showing items 1 to 35 of
35
with 100 items per page.
- Q66396125 description "clinical trial" @default.
- Q66396125 description "ensayu clínicu" @default.
- Q66396125 description "klinisch onderzoek" @default.
- Q66396125 description "клінічне випробування" @default.
- Q66396125 name "Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus" @default.
- Q66396125 name "Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus" @default.
- Q66396125 type Item @default.
- Q66396125 label "Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus" @default.
- Q66396125 label "Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus" @default.
- Q66396125 prefLabel "Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus" @default.
- Q66396125 prefLabel "Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus" @default.
- Q66396125 P1132 Q66396125-5C335AF9-12AD-48DC-8F25-1EDC4C6608A5 @default.
- Q66396125 P1476 Q66396125-C8BD4804-11CF-4246-95F8-F00C4166D29D @default.
- Q66396125 P17 Q66396125-AAB96561-EE4F-4311-9841-8E8E6807E0BD @default.
- Q66396125 P1813 Q66396125-608C2F90-6818-4A9C-90B3-98FF87436A88 @default.
- Q66396125 P2899 Q66396125-F60B7581-5212-44EA-8E49-A2A6A8AC9EC2 @default.
- Q66396125 P3098 Q66396125-6059E0FD-DA45-4C26-A2AA-E262353F7647 @default.
- Q66396125 P31 Q66396125-23FBC23F-3E32-41BB-8A75-1F284EEBF1D4 @default.
- Q66396125 P4135 Q66396125-ECBC025C-6DC5-4153-9E01-FE469B10E328 @default.
- Q66396125 P4844 Q66396125-2DD24323-F4B3-434F-8AFD-765EA5DDE923 @default.
- Q66396125 P580 Q66396125-A4C8D589-BBDB-43F4-8C29-6C27D86F7370 @default.
- Q66396125 P582 Q66396125-7628E0F7-9278-4E75-89B3-42AE4522E686 @default.
- Q66396125 P8363 Q66396125-13C27BEF-F8C5-4748-94FF-9446E21AF479 @default.
- Q66396125 P1132 "+112" @default.
- Q66396125 P1476 "Study of the Immune Response T Anti-tumoral Cluster of Differentiation 4 (CD4) for Patients Treated for a Metastatic Breast Cancer by Everolimus Within the Framework of Its Marketing Authorization" @default.
- Q66396125 P17 Q142 @default.
- Q66396125 P1813 "EVERIMMUN" @default.
- Q66396125 P2899 "+18" @default.
- Q66396125 P3098 "NCT02854618" @default.
- Q66396125 P31 Q30612 @default.
- Q66396125 P4135 "+85" @default.
- Q66396125 P4844 Q32089 @default.
- Q66396125 P580 "2015-06-01T00:00:00Z" @default.
- Q66396125 P582 "2022-05-01T00:00:00Z" @default.
- Q66396125 P8363 Q78089383 @default.